# Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands

Folgerdiena M. de Vries, BSc[1],*, Petra Denig, PhD[2], Sipke T. Visser, MSc[1], Eelko Hak, PhD[1], Maarten J. Postma, PhD[1]

[1]Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands; [2]Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

A B S T R A C T

**Background:** Statins are lipid-lowering drugs that reduce the risk of cardiovascular events in patients with diabetes. **Objectives:** The objective of this study was to determine whether statin treatment for primary prevention in newly diagnosed type 2 diabetes is cost-effective, taking nonadherence, baseline risk, and age into account. **Methods:** A cost-effectiveness analysis was performed by using a Markov model with a time horizon of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch population of primary prevention patients with newly diagnosed diabetes from the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database, using the United Kingdom Prospective Diabetes Study risk engine. Statin adherence was measured as pill days covered in the IADB.nl pharmacy research database. Cost-effectiveness was measured in costs per quality-adjusted life-year (QALY) from the health care payers' perspective. **Results:** For an average patient aged 60 years, the base case, statin treatment was highly cost-effective at €2245 per QALY. Favorable cost-effectiveness was robust in sensitivity analysis. Differences in age and 10-year cardiovascular risk showed large differences in cost-effectiveness from almost €100,000 per QALY to almost being cost saving. Treating all patients younger than 45 years at diabetes diagnosis was not cost-effective (weighted cost-effectiveness of almost €60,000 per QALY). **Conclusions:** Despite the nonadherence levels observed in actual practice, statin treatment is cost-effective for primary prevention in patients newly diagnosed with type 2 diabetes. Because of large differences in cost-effectiveness according to different risk and age groups, the efficiency of the treatment could be increased by targeting patients with relatively higher cardiovascular risk and higher ages.
*Keywords:* cardiovascular risk management, cost-effectiveness, statins, type 2 diabetes.

Copyright © 2014, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

## Introduction

The prevalence of diabetes is growing in The Netherlands, as in many countries worldwide, because of aging of the population and the occurrence of diabetes at younger ages [1]. Patients with type 2 diabetes have an increased risk of cardiovascular complications [2]. These complications reflect a high burden for health and cause substantial costs related to diabetes [3–5]. Statins are lipid-lowering drugs that have been shown to reduce the risk of cardiovascular and cerebrovascular events in patients with diabetes [6–8]. After 2006, the Dutch guidelines for diabetes and cardiovascular risk management changed and recommended statin treatment for the prevention of cardiovascular events for practically all patients with type 2 diabetes, unless they have a low cardiovascular risk [9,10]. Although risk tables changed in recent guidelines, it was found using different risk calculation methods that few patients with type 2 diabetes are at such low risk [11]. Also, in other countries, statin treatment is recommended for a large proportion of the diabetes population [12,13].

Previous pharmacoeconomic analyses on the primary prevention of cardiovascular and cerebrovascular events estimated that statin treatment is likely to be cost-effective in patients with type 2 diabetes [14–16]. These pharmacoeconomic results, however, are limited because they made use of data from the same clinical trial, which included a restricted patient population with high adherence levels. Adherence to statins is a well-known problem in clinical practice [17,18], and therefore important to take into account when assessing cost-effectiveness. Furthermore, attention should be paid to the risk level where treatment becomes cost-effective. Greving et al. [19] recently demonstrated for a hypothetical primary prevention population that statins were not cost-effective in persons at low risk in The Netherlands. Whether this may also be true for patients with type 2 diabetes at relatively low risk is not known. Earlier detection of type 2 diabetes and younger age of these patients cause that patients with lower risk for cardiovascular and cerebrovascular events are being identified and treated with statins [20]. For better guidance on treatment decisions, it is important to gain an insight into the cost-effectiveness of statin treatment in patients with type 2 diabetes using the cardiovascular risk estimates and adherence levels based on patient data from actual practice.

---

The objective of this study was to determine whether statin treatment for primary prevention, started at the time of diagnosis of type 2 diabetes, is cost-effective from a health care payers' perspective in The Netherlands, taking nonadherence, baseline risk, and age into account.

## Methods

### Markov Model

The cost-effectiveness of statin treatment for primary prevention, started at the time of type 2 diabetes diagnosis, was determined with a Markov model (Fig. 1). A population with statin treatment and a population without the use of any lipid-regulating treatment were simulated with the model. The design of the model was the same for both populations, with only probabilities of transitions to events changed by the use of statin treatment. We assumed that all patients got optimal secondary prevention. Differences in costs and effects were evaluated.

Because we aimed to determine the cost-effectiveness of primary prevention, all patients started in the "otherwise healthy" state, that is, patients with type 2 diabetes having experienced no previous cardiovascular or cerebrovascular event. Ten different health states were included in the Markov model, and patients could shift to another health state after a 1-year cycle, for which half-cycle corrections were performed [21]. The adverse events rhabdomyolysis and myopathy were taken into account. Patients who had experienced an adverse event returned to the otherwise healthy state in the next run. The correction for patients discontinuing treatment because of adverse events was done by applying real-world adherence rates, which include patients who have stopped statin treatment after an adverse event. In the base case, a time horizon of 10 years was used, because we were focusing on primary prevention.

### Event Probabilities

Probabilities of shifting to an event state were taken from results of the United Kingdom Prospective Diabetes Study (UKPDS) risk engine, with which the annual rates for an event over a 10-year period can be calculated (see below) [22–24]. When patients experienced a nonfatal event in the model, they moved to the "postevent" state in the next cycle. All patients in the cohort experienced age-specific probabilities of dying from other causes. These probabilities were taken from the Dutch lifetime tables, taking the ageing of the Dutch population explicitly into account [25]. Because we evaluated primary prevention, we used a

simplified adjustment on the death rate after the occurrence of an event. That is, for patients in postevent states, the probabilities of death, taken from Dutch lifetime tables, were increased twofold based on previous studies [26,27].

The UKPDS risk engine was used to estimate the patients' 10-year risks for coronary heart disease (CHD) and stroke on the basis of patient characteristics, including age, lipid ratio, and other risk factors [22–24]. These patient characteristics were obtained from the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. The GIANTT database contains anonymised longitudinal information retrieved from electronic medical records of general practitioners and is maintained by the University Medical Center Groningen [28]. Information on age, lipid ratio, and smoking status was taken at the time of type 2 diabetes diagnosis, in line with Dutch guidelines that advise statin treatment for patients with type 2 diabetes immediately after diagnosis for practically all patients [9,10]. Because it is to be expected that hemoglobin $A_{1c}$ and blood pressure values will decrease after diagnosis because of the initiation of glucose-lowering and blood pressure–lowering treatment, we averaged the values for hemoglobin $A_{1c}$ and systolic blood pressure at 1 and 2 years after the diagnosis for estimating the 10-year risks. In this way, we aimed to estimate the risk factor levels achieved with such treatment and assumed that patients remain adequately treated for these other risk factors during follow-up. This allowed us to assess the risk reduction of statin treatment in addition to the risk reduction caused by concurrent treatment for the other risk factors. Clinical data retrieved from the GIANTT database for a cohort of patients diagnosed with type 2 diabetes in 2007, 2008, or 2009 were inserted into the UKPDS risk engine. Patients with a history of CHD or stroke (International Classification of Primary Care codes K75, K76, and K90) [29] or who had a prescription for any lipid-regulating treatment (Anatomical Therapeutic Chemical (ATC) C10) [30] during the year before diagnosis were excluded.

In total, 4683 patients with newly diagnosed type 2 diabetes without a history of cardiovascular and cerebrovascular events were extracted from the GIANTT database and included in the UKPDS risk engine. The average patient was aged 61.3 years, and there were slightly more women than men (51.4%). On average, patients had a hemoglobin $A_{1c}$ level of 6.7%, systolic blood pressure of 140 mm Hg, and a lipid ratio of 5 (total cholesterol/high-density lipoprotein cholesterol); 18% of the patients were smokers; and 1.6% had atrial fibrillation according to their medical records.

The average 10-year risk of the population aged 25 to 65 years at type 2 diabetes diagnosis was 16% for CHD, 8% for fatal CHD, 4% for stroke, and 0.7% for fatal stroke. Stratifying the 10-year



Fig. 1 – Markov model. CHD, coronary heart disease.

## Table 1 – Incidence, effectiveness, disutilities and cost data for the base case.

| Parameter | Base case | Distribution | Data source | Reference |
|---|---|---|---|---|
| **Annual risks** | | | | |
| CHD yearly risk, % (10-year risk) | 1.7, 1.8, 1.9, 2.0, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5 (21%) | Beta | Real world data from GIANTT database inserted in UKPDS risk engine | - |
| Fatal CHD yearly risk, % (10-year risk) | 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 (11%) | Beta | Real world data from GIANTT database inserted in UKPDS risk engine | - |
| Stroke yearly risk, % (10-year risk) | 0.3, 0.4, 0.4, 0.5, 0.6, 0.6, 0.7, 0.8, 0.9, 1.0 (6%) | Beta | Real world data from GIANTT database inserted in UKPDS risk engine | - |
| Fatal stroke yearly risk, % (10-year risk) | 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0,1, 0.2, 0.2 (1%) | Beta | Real world data from GIANTT database inserted in UKPDS risk engine | - |
| Myopathy (per 100,000 person years) | 11 | Beta | Systematic review | 31 |
| Rhabdomyolysis (per 100,000 person years) | 3 | Beta | Systematic review | 31 |
| Overall mortality rate (10-year risk) | 12% | - | Actual rates | 25 |
| **Statin treatment effectiveness (relative risk)** | | | | |
| MI | 0.69 | Lognormal | Meta-analysis | 8 |
| Stroke | 0.70 | Lognormal | Meta-analysis | 8 |
| **Mean adherence rate** | | | | |
| First year | 81% | Beta | Real world data from the IADB.nl prescription database | - |
| Second year | 77% | Beta | Real world data from the IADB.nl prescription database | - |
| Third until tenth year | 75% | Beta | Real world data from the IADB.nl prescription database | - |
| **Disutility** | | | | |
| MI | 0.06 | Triangular | Meta-analysis | 37 |
| Stroke | 0.22 | Triangular | Meta-analysis | 37 |
| Act of taking statin | -0.001 | Triangular | Assumption | 38,39 |
| **Annual cost data (€)** | | | | |
| Statin treatment | | | | |
|   Simvastatin 40 mg | € 7.30 | - | Official tariff | 40 |
|   Doctor visits | € 59.5 | - | Official tariff | 41 |
|   Laboratory fee | € 20.3 | - | Official tariff | 42 |
|   Pharmacists fee | € 24.3 | - | Official tariff | 43 |
| Myopathy | € 59.5 | Gamma | Assumption | - |
| Rhabdomyolysis | € 11,126 | Gamma | Cost study | 44 |
| MI | | | | |
|   First year | € 5,012 | Gamma | Cost study | 45 |
|   Subsequent years | € 1,885 | Gamma | Cost study | 5 |
| Stroke | | | | |
|   First year | € 13,480 | Gamma | Cost study | 46 |
|   Subsequent years | € 1,885 | Gamma | Cost study | 5 |
| Death | € 2,902 | Gamma | Assumption | 19 |

CHD, coronary heart disease.

cardiovascular risks by age showed that age has a large effect on the risk. Patients aged 56 to 65 years at diagnosis of type 2 diabetes had an average risk of 21% for CHD, 11% for fatal CHD, 6% for stroke, and 1% for fatal stroke, and patients aged 46 to 55 years had risks of 15%, 6%, 3%, and 0.4%, respectively. Patients aged 36 to 45 years were estimated to have an average risk of 9% for CHD, 3% for fatal CHD, 1% for stroke, and 0.1% for fatal stroke.

### Statin Treatment and Adherence

Statin efficacy was modeled by implementing the relative risk reduction found in a recent meta-analysis of randomized clinical trials on the primary prevention of cardiovascular and cerebrovascular events in patients with diabetes with statins [8]. Overall relative risk reductions of 31% for nonfatal CHD and fatal CHD

and 30% for nonfatal stroke and fatal stroke were applied. The risks for adverse events myopathy and rhabdomyolysis were taken from a systematic review [31].

Adherence to statins was modeled by using real-world data from the IADB.nl database, which is a pharmacy research database in The Netherlands with a sample of the Dutch population of 500,000 persons. Patients with type 2 diabetes and no history of cardiovascular and cerebrovascular events were identified by the use of medication proxies (Appendix I). Statin adherence rates were defined as the percentages of pill days covered (PDC) [32]. Adherence rates were measured for patients starting statin treatment from 2008 up to and including 2010 (ATC C10AA, C10BA, and C10BX). Patients were considered as a starter of statin treatment when they did not use any lipid-lowering medication (ATC C10) in the year before the start of the statin treatment. Adherence rates were measured up to a maximum of 3 years, and in the base case

**Table 2 – One-way sensitivity analyses (base case values between brackets).**

| Assumption | Cost-effectiveness |
|---|---|
| Base case | €2,245 |
| Statin costs (€7.3) | |
| €18.5 (actual costs IADB.nl population) | €2,644 |
| €50 | €3,766 |
| €100 | €5,547 |
| Myopathy (11 op 100.000 years) | |
| 100 | €2,247 |
| Discounting rate (effects 1.5%;costs 4%) | |
| Effects 3%; costs 3% | €3,041 |
| Effects 4%; costs 4% | €3,144 |
| Disutility taking a pill (0.999) | |
| No disutility | €2,155 |
| Time horizon (10 years) | |
| 5 years | €12,424 |
| Adherence rate (81%, 75%, 77% respectively first, second and subsequent years) | |
| Full adherence (80-100% PDC) in all years | €1,534 |
| 50% adherence in all years | €3,312 |
| Adherence decreasing 2% each year after year 3 | €2,266 |
| Adherence decreasing 5% each year after year 5 | €2,297 |
| Relation statin efficacy and non-adherence (≥80%=1;20-80%=linear;≤20%=0) | |
| ≥70%=1;30-70%=linear;≤30%=0 | €2,217 |
| ≥80%=1;0-80%=linear | €2,175 |
| ≥60%=1;0-50%=linear | €2,108 |
| UKPDS risk overestimation | |
| Lowering risk with 50% | €6,500 |

we assumed that statin adherence stayed constant after year 3, as was observed in a previous study [17].

Nonadherence was modeled by reducing the statin efficacy. Statin treatment with 80% or more PDC was assumed to be associated with full efficacy [33]. Patients with 20% or less PDC were assumed to be associated with no efficacy of the statin treatment. Efficacy of intermediary levels of PDC was approximated with linear interpolation in the base case because studies indicate that there is a linear association between adherence levels and reductions in low-density lipoprotein cholesterol and in hospitalizations [34–36].

In 1660 patients who started statin treatment, the mean PDC was 81% during their first year of statin use. Adherence rates decreased to 77% and 75% in year 2 and 3, respectively. In total, 1049 patients were followed for at least 2 years and 479 for 3 years. Because we allowed new users to be included during the study period, some patients could be followed only for 1 year. The decrease in the number of patients in the follow-up years was mainly due to later inclusion into the study rather than early dropout.

### Health Effects and Costs

We determined the difference in quality-adjusted life-years (QALYs) between no lipid-regulating treatment and treatment with a statin. QALYs were calculated by multiplying the time in a specific health state with the quality of life associated with the health state. For patients experiencing a CHD or stroke, disutility scores were 0.06 and 0.22, respectively [37]. These utility scores were constant over time. A small disutility of 0.001 for taking a statin pill every day was included [38,39].

All cost estimates were updated to 2012 euros with the Dutch consumer price indices (http://statline.cbs.nl). Annual costs for statin treatment in the base case were based on statin pill costs (€7.3 for 40 mg generic simvastatin) [40], two GP visits (€59.5) [41],

**Table 3 – Outcomes of the cost-effectiveness analysis stratified by age and risk for CHD and stroke**

| Age (y) | | 10-y risk for CHD; fatal CHD; stroke; fatal stroke | Proportion per age group | QALYs 1,000 patients | Costs per 1,000 patients (€) | Cost-effectiveness |
|---|---|---|---|---|---|---|
| <45* | 1. | 3; 1; 1; 0 | 27.5 | −8 | 814,012 | Inferior[†] |
| | 2. | 6; 1; 1; 0 | 28.5 | −3 | 789,256 | Inferior[†] |
| | 3. | 9; 3; 1; 0 | 21.8 | 11 | 738,926 | €66,537[‡] |
| | 4. | 13; 4; 2; 0 | 9.5 | 43 | 689,576 | €16,085[§] |
| | 5. | 16; 6; 3; 1 | 12.7 | 77 | 634,993 | €8,223[§] |
| 45–55[‖] | 1. | 6; 2; 1; 0 | 21.1 | 9 | 758,216 | 88,440[†] |
| | 2. | 10; 4; 2; 0 | 28.7 | 49 | 674,895 | €13,828[§] |
| | 3. | 15; 6; 3; 0.5 | 20.8 | 75 | 623,327 | €8,345[§] |
| | 4. | 20; 7; 4; 0.5 | 16.7 | 96 | 559,641 | €5,810[§] |
| | 5. | 26; 10; 5; 1 | 12.6 | 145 | 486,131 | €3,353[§] |
| 55–65[¶] | 1. | 6; 3; 3; 1 | 6.8 | 43 | 638,881 | €14,824[§] |
| | 2. | 10; 4; 3; 1 | 30.4 | 61 | 618,594 | €10,119[§] |
| | 3. | 21; 11; 6; 1 | 34.7 | 193 | 432,890 | €2,245[§] |
| | 4. | 27; 13; 7; 1 | 15.9 | 197 | 382,633 | €1,939[§] |
| | 5. | 35; 24; 9; 2 | 12.3 | 453 | 276,148 | €609[§] |

Note. inferior = no cost-effectiveness is calculated because of the negative effect on QALYs. CHD, coronary heart disease; QALY, quality-adjusted life-year.

* Weighted cost-effectiveness for treating all patients with diabetes younger than 45 years in The Netherlands = €57,244.

[†] >€80,000.

[‡] €50,000–€80,000.

[§] <€20,000.

[‖] Weighted cost-effectiveness for treating all patients with diabetes between 45 and 55 years in The Netherlands = €8,295.

[¶] Weighted cost-effectiveness for treating all patients with diabetes between 55 and 65 years in The Netherlands = €2,480.

#€20,000–€50,000.

**Fig. 2 – Tornado diagram; all parameters are increased and decreased with 25%. CHD, coronary heart disease.**

annual lipid spectrum testing (€20.3) [42,44], and four pharmacists' prescription fees (€23) [43]. Event costs were based on the literature (Table 1).

### Economic Analysis

The model was run over a time horizon of 10 years. Costs were discounted at 4% and health effects at 1.5%, following the Dutch guidelines [41]. In the base case, a 60-year-old patient was assessed, based on the average age of 61.3 years at type 2 diabetes diagnosis in the GIANTT database population. Mean 10-year cardiovascular risks of patients aged 56 to 65 years at type 2 diabetes diagnosis were used. With the use of a tornado diagram, the effect of the parameters on the outcome of the cost-

effectiveness was assessed. In addition, the effects of age and baseline risk for CHD and stroke were evaluated. To assess the effect of individual parameters that may vary between countries or that were based on assumptions, one-way sensitivity analyses were performed. This included sensitivity analyses for statin costs, adverse event rates, discounting rates, disutility of taking a pill every day, time horizon, adherence rates, and relation between nonadherence and efficacy. Parameter variations tested are presented in Table 2. We also included a one-way sensitivity analysis to account for the possible overestimation by using the UKPDS risk engine, assuming a maximum reduction of 50% in the estimates [47]. Finally, a probabilistic sensitivity analysis with 5000 iterations was performed to deal with parameter uncertainty [48]. The parameter distributions used are listed in Table 1.



**Fig. 3 – Cost-effectiveness acceptability curves from the probabilistic sensitivity analysis.**

## Results

### Economic Analysis

In the base case, cost-effectiveness is €2245 per QALY (Table 2). Sensitivity analyses were performed to investigate differences in risks for CHD and stroke according to age. In Table 3, the outcomes of the cost-effectiveness analysis are shown stratified by age and 10-year risks for CHD and stroke. The risks chosen for each age group were based on actual risk ranges within the GIANTT database population. Treating all type 2 patients younger than 45 years for primary prevention of cardiovascular and cerebrovascular events was not cost-effective, with costs of €57,243 per QALY. Treating all patients aged 45 to 55 years at diagnosis was cost-effective, with costs of €8295 per QALY. For 21.1% of the patients, however, cost-effectiveness would be high and not cost-effective (Table 3).

The tornado diagram (Fig. 2) shows that the efficacy of the statins, the baseline risk for CHD and stroke, and the adherence rates have a large effect on the outcome of the cost-effectiveness. In the one-way sensitivity analyses (Table 2), statin costs also have a major effect on the cost-effectiveness. In The Netherlands, statin costs for 40 mg generic simvastatin were only €7.3 annually. The actual annual statin costs per patient in the IADB.nl population were €18.5, which results in a negative effect on cost-effectiveness (€2644 per QALY). Changing the time horizon to 5 years will lead to a substantial increase in costs (€12,424 per QALY). Increasing adherence to statin treatment will improve cost-effectiveness. Full adherence reduces the costs to €1534 for the base case. However, changing the assumptions on the adherence rate after year 3 does not have a great effect on cost-effectiveness (Table 2).

The acceptability curves of the probabilistic sensitivity analyses in Figure 3 show that the probability that statin treatment is cost-effective for the average 60-year-old patient is 100%, using a threshold of €20,000 per QALY. Considering the average 40-year-old patient, the analysis shows that with this threshold of €20,000 per QALY, the probability that it is cost-effective is less than 15% (Fig. 3).

## Conclusions

We estimated that statin treatment for primary prevention starting at the time of diagnosis of type 2 diabetes is cost-effective at €2245 per QALY in the base case. There is great diversity in the risks for CHD and stroke in the type 2 diabetes population. Differences in age and 10-year risks for CHD and stroke result in large differences in cost-effectiveness from losing QALYs to being almost cost neutral. With the adherence rates seen in practice, it can be concluded that treating all patients younger than 45 years with type 2 diabetes at diagnosis with statins for primary prevention is not cost-effective. For patients aged between 45 and 55 years at diagnosis, statin treatment is cost-effective except when the 10-year risk for CHD is as low as 6%. For the other patients, statin treatment is expected to be cost-effective.

Our finding that statin treatment for primary prevention is cost-effective for the average 60-year-old patient is in line with other pharmacoeconomic analyses [14–16]. The finding that statin treatment is not cost-effective in patients at low risk is in line with findings from Greving et al. [19]. Cost-effectiveness, however, appears slightly better in our diabetes population. For a 65-year-old patient with a 10-year risk of 15%, Greving et al. estimated the costs at €12,652 per QALY whereas we estimated the costs at €10,119 per QALY for a 60-year-old patient with a 10-year risk of 13%.

Currently, there are more than 800,000 patients with diabetes in The Netherlands [49]. Within the GIANTT database population,

14% of the patients have a cardiovascular history, implying that 688,000 patients might be eligible for primary prevention with statin treatment. With the current price levels, such statin treatment would cost the Dutch health care system around €75.7 million each year. The broad range for cost-effectiveness between the individual patients suggests that the efficiency of the treatment could be increased by focusing on patients with higher cardiovascular risk and higher ages. Within the GIANTT database primary prevention population, 19% of the patients had an age at diagnosis of less than 50 years in whom starting statin treatment at the time of diagnosis may not be cost-effective.

Cost-effectiveness was assessed taking various parameters into account, such as adherence and adverse events. Adherence to statin treatment obviously plays an important role in cost-effectiveness analysis. In our study population, adherence rates for statin treatment were higher than reported in other studies [17,50]. Nevertheless, further improving adherence would lead to improvements in cost-effectiveness. Furthermore, in the base-case analysis, the statin costs of 40 mg generic simvastatin (€7.3) were applied; use of the average annual costs of statin treatment from the IADB.nl population (€18.5) has a minor negative effect on cost-effectiveness. Dutch guidelines [9,10] recommend 40 mg simvastatin or 40 mg pravastatin (€16.10) when statin treatment is started. Treating patients with 40 mg simvastatin has beneficial effects on cost-effectiveness. Nevertheless, some patients need a switch to more expensive statins to reach lipid goals [51]. In the base-case analysis, we chose a time horizon of 10 years. Shortening the time horizon to 5 years clearly affects the cost-effectiveness, indicating that primary prevention with statins is especially beneficial in patients with diabetes who can and will take the treatment for a longer period.

### Strengths

We analyzed the baseline risk of a population of patients with type 2 diabetes using observational patient data that were inserted into the UKPDS risk engine. Because the GIANTT database cohort includes an unrestricted population of patients with type 2 diabetes in primary care, these data better reflect the population treated with statins in actual practice as compared to the patients included in trials. Adherence rates were also measured in the actual population. Both populations were taken from the Northern part of The Netherlands. Using the tornado diagram, the parameters that have a large effect on the outcome of the cost-effectiveness analysis—such as the efficacy of statins, the baseline risk for CHD and stroke, and adherence rates—were analyzed in detail. From this, it becomes clear that the utilities and the drug costs did not have a large effect on the results. The strength of this study is that we stratified the patients according to age. As a result of the broad ranges in the 10-year risks for CHD and stroke between the different age groups, broad variations in cost-effectiveness could be shown.

### Limitations

First, the UKPDS risk engine was used for determining cardiovascular risks for patients with type 2 diabetes. There is evidence that the UKPDS risk engine overestimates the risks for CHD and stroke [47,52]. As shown in the sensitivity analysis, the costs per QALY could more than double when risks are overestimated by a factor of 2. It seems, however, that at the risk levels seen in the primary prevention diabetes population, the overestimation is probably not that high [47]. Second, adherence rates of the patients were measured in a pharmacy research database in which the indication of the patient was not known. Medication proxies had to be used for identifying diabetes primary prevention patients. The proxy for diabetes is known to give a high sensitivity [53]. The proxy for primary prevention showed a high

sensitivity of 85%. Around 15% of the included patients, however, can be expected to be secondary prevention patients. Third, the adherence rates were measured only for the first 3 years and assumed to stay constant over time afterwards. In addition, for the intermediate adherence levels, we assumed a linear relation with the efficacy. Although there is some evidence that these assumptions are acceptable [17,34–36], we tested them in the sensitivity analyses, which showed that various changes in the assumptions did not have much effect on the results. We used real patient data for the risk estimation and adherence rates, but treatment efficacy, disutilities, and cost data were based on literature. For statin efficacy as well as for post–myocardial infarction and poststroke utilities, we made use of estimates from meta-analyses, which applied minimum criteria for including appropriate data. For costs, we tried to retrieve the most recent data available but had to rely on multiple sources published in the past decade. Only direct health care costs were included. Including indirect costs would obviously be favorable for cost-effectiveness [45,46].

This study is an illustration for The Netherlands. In The Netherlands, statin costs are very low, and such medication is reimbursed for all patients. Other countries may have higher statin costs or higher nonadherence rates due to patient co-payments, and cost-effectiveness might be less favorable. The population used in this analysis was from the northern part of The Netherlands, which is known to have a lower rate of immigrants and a lower socioeconomic status in comparison to other parts of The Netherlands [54,55]. As one could speculate that this might affect the estimated risks for cardiovascular events and the adherence rates in opposite directions, it is not clear to what extent this would result in relevant changes in our findings.

We used a time horizon of 10 years with cycle lengths of 1 year. Because of data availability, it was not possible to shorten the cycle length but by performing half-cycle corrections, the effect of this longer cycle length was minimized. Because we aimed to assess the effect of primary prevention of cardiovascular and cerebrovascular events, we did not perform a lifetime analysis but did shorten the time horizon in the sensitivity analysis to 5 years.

In general, primary prevention with statin treatment at the time of diagnosis is not cost-effective for all patients with type 2 diabetes. In the recent Dutch guidelines for cardiovascular management, 40 years is mentioned as the age limit for patients with diabetes below which statin treatment would seldom be indicated [9]. Our study indicates that this age limit may be set higher because, on average, starting statin treatment in patients younger than 45 years is not expected to be cost-effective. However, our results indicate that statin treatment, even with the levels of nonadherence and variations in choice of statin seen in actual practice, is highly cost-effective for patients older than 55 years at diagnosis with a time horizon of 10 years. Although it is acknowledged that there is no single treatment appropriate for all patients and the individual risk profile of a patient should be considered, these simple age-based recommendations could be helpful for guiding practice.

## Supplemental Materials

Supplemental materials accompanying this article can be found in the online version as a hyperlink at http://dx.doi.org/10.1016/j.jval.2013.12.010 or, if a hard copy of article, at www.valueinhealth journal.com/issues (select volume, issue, and article).

R E F E R E N C E S

[1] The National Institute for Public Health and the Environment. Diabetes in the Netherlands 2007. Available from: http://www.rivm.nl/bibliotheek/rapporten/260322001.pdf. [Accessed April 9, 2013].

[2] American Heart Association. Cardiovascular disease & diabetes statistics update 2010. Available from: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp. [Accessed April 9, 2013].

[3] Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442–50.

[4] Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil 2009;16:576–82.

[5] Redekop WK, Koopmanschap MA, Rutten GE, et al. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus: results from 29 general practices. Diabet Med 2002;19:246–53.

[6] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.

[7] Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. Bmj 2005;330:821.

[8] de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012;72:2364–73.

[9] NHG-standard Cardiovasculair risicomanagement (Eerste herziening). Huisarts Wet 2012;55:14–28.

[10] Wiersma TJ, Goudswaard AN. NHG-Standard Cardiovascular Risk Management [in Dutch]. Houten, The Netherlands: Bohn Stafleu van Loghum, 2006.

[11] De Grauw W, Bakx C, Van Gerwen W. Iedere patiënt met diabetes mellitus type 2 een statine, tenzij… Verwarring na twee standaarden? Huisarts Wetenschap, jaargang 2007;4:144–7.

[12] American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012;35(Suppl. 1):S11–63.

[13] National Collaborating Centre for Chronic Conditions. NICE clinical guideline 2006. In: Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008.

[14] Lafuma A, Colin X, Solesse A. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. Arch Cardiovasc Dis 2008;101:327–32.

[15] Raikou M, McGuire A, Colhoun HM, et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733–40.

[16] Annemans L, Marbaix S, Webb K, et al. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the Belgian population. Clin Drug Investig 2010;30:133–42.

[17] Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850–5.

[18] Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154–9.

[19] Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011;342:d1672.

[20] Baan CA, Schoemaker CG. Diabetes tot 2025 Preventie en zorg in samenhang (Rapport 260322004/2009). Bilthoven. The Netherlands: RIVM, 2009.

[21] Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322.

[22] Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671–9.

[23] Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81.

[24] Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004;27:201–7.

[25] Statistics Netherlands. Lifetables: Dutch Population by Age and Sex. Den Haag, The Netherlands: Statistics Netherlands, 2010.

[26] Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

[27] Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001;32:2131–6.

[28] Voorham J, Denig P. Computerized extraction of information on the quality of diabetes from text in electronic medical patient records of general practitioners. J Am Med Inform Assoc 2007;14:349–54.

[29] Lamberts H, Wood M, eds. International Classification of Primary Care (ICPC). Oxford: Oxford University Press, 1987.

[30] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index. Available from: http://www.whocc.no/atc_ddd_index/. [Accessed March 13, 2013].

[31] Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C–60.

[32] Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3–12.

[33] Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010;4:462–71.

[34] Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30.

[35] Parris ES, Mohn LA, Lawrence DB, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595–9.

[36] Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin 2013;29:175–80.

[37] Lung TW, Hayes AJ, Hayen A, et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res 2011;20:1669–778.

[38] Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992;12:239–49.

[39] Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326–36.

[40] Dutch Health Care Insurance Board. Drug costs. Available from: www.medicijnkosten.nl. [Accessed April 7, 2013].

[41] Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Guideline for Costing Research: Methods and Standardized Prices for Economic Evaluations in Health Care. The Netherlands: Health Care Insurance Board, 2010.

[42] Dutch Healthcare Authority. Rates for various professionals and various laboratory tests. 2010. Available from: www.nza.nl. [Accessed March 8, 2013].

[43] Farmacotherapeutisch Kompas. Rates for pharmacy fee. Available from: http://www.fk.cvz.nl/voorna/i/inl%20de%20kosten%20voor%20farmaceutische%20zorg.asp. [Accessed April 9, 2013].

[44] Pletcher MJ, Lazar L, Bibbins-Dommingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243–54.

[45] Soekhlal RR, Burgers LT, Redekop WK, et al. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J 2013;21:230–5.

[46] Kroes ME. Nationaal Programma Grieppreventie: het succes van de griepprik (Rapport 162). Amstelveen, The Netherlands: College voor zorgverzekeringen, 2003.

[47] van der Heijden AA, Ortegon MM, Niessen LW, et al. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn Study. Diabetes Care 2009;32:2094–8.

[48] Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press, 2006.

[49] National Institute for Public Health and the Environment. Meer dan 800.000 mensen met diabetes in Nederland; toename fors. Available from: http://www.rivm.nl/Documenten_en_publicaties/Algemeen_Actueel/Nieuwsberichten/2013/Meer_dan_800_000_mensen_met_diabetes_in_Nederland_toename_fors. [Accessed October 31, 2013].

[50] Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462–7.

[51] Harley CR, Gandhi S, Blasetto J, et al. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother 2007;5:185–94.

[52] Van Dieren S, Peelen LM, Nöthlings U. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011;54:264–70.

[53] Voorham J, Haaijer-Ruskamp FM, van der Meer K, et al. Kwaliteit van de behandeling van type 2-diabetes: resultaten van het GIANTT-project 2004-2007. Ned Tijdschr Geneeskd 2010;154:A775.

[54] Nationale atlas volksgezondheid. Socioeconomic status 2010. Available from: http://www.zorgatlas.nl/beinvloedende-factoren/sociale-omgeving/ses/sociaaleconomische-status/. [Accessed April 10, 2013].

[55] Nationale atlas volksgezondheid. Demographic ethnicity. Available from: http://www.zorgatlas.nl/beinvloedende-factoren/demografie/etniciteit/. [Accessed April 10, 2013].